Myriad Collaborative Research Registry™ – One of the largest pan-cancer registries freely available for research use.
The Myriad Collaborative Research Registry advances patient care by combining structured clinical data with genetic and genomic results. The overarching goal is to create an environment for improving and advancing cancer care.
The registry includes the following de-identified data:
Once granted access and trained, clinicians and researchers can use the research portal for immediate exploration. Queries and analyses conducted can foster further research opportunities. Download patient consent form.
Registry access form
If you would like to access the registry or submit a research project concept form, please include your contact information and someone from our team will contact you soon.
Once access is granted to the research portal, users will be able to carry out queries and analyses that will help inform and foster research opportunities.
Some examples include:
The trainer orienting you to MCRR dashboard is available for support to navigate the registry. Contact [email protected] for triage to other experts as appropriate.
Germline hereditary cancer test capable of identifying risk and providing insights for treatment options for 11 hereditary cancers.
FDA-approved germline companion diagnostic test for patients with breast, ovarian, pancreatic and prostate cancer.
The most comprehensive FDA-approved tumor test that determines HRD status in women with ovarian cancer.
Precise™ Tumor is a pan-cancer, comprehensive laboratory test that uses state-of-the-art, next-generation sequencing to discover and target important variants within tumors.
Prolaris® is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to guide the best treatment decisions for prostate cancer patients.